정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1430 | Not yet recruiting | Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes | COVID-19 Pneumonia | Biological: Covid-19 vaccine (0-1-4 schedule) Biological: Covid-19 vaccine (0-1-6 schedule) |
Phase 4 | China National Biotec Group Company Limited, Guizhou Center for Disease Control and Prevention, Hunan Center for Disease Control and Prevention, Fujian Center for Disease Control and Prevention, Wuhan Institute of Biological Products Co., Ltd | INDUSTRY | 1440 | All | 60 Years | Nan'an Center for Disease Control and Prevention, Quanzhou, Fujian, China Songtao Miao Autonomous County Center for Disease Control and Prevention, Tongren, Guizhou, China You County Center for Disease Control and Prevention, Zhuzhou, Hunan, China |
| 1429 | Recruiting | Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19 | Covid19 | Drug: intranasal ivermectin spray | Phase 3 | South Valley University | OTHER | 150 | All | 18 Years | Zaky Aref, Qin?, Qina, Egypt |
| 1428 | Completed | Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment | Covid19 | Drug: Azithromycin / Ivermectin / Ribaroxaban / Paracetamol Drug: Azithromycin / Ribaroxaban / Paracetamol |
Phase 3 | Gilberto Cruz Arteaga, Coordinacion de Investigacion en Salud, Mexico | OTHER_GOV | 114 | All | 18 Years | Alma Italia Guerrero Martinez, Mexico, Distrito Federal, Mexico |
| 1427 | Completed | Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia. | COVID-19 | Drug: EXO 1 inhalation Drug: EXO 2 inhalation Drug: Placebo inhalation |
Phase 2 | State-Financed Health Facility "Samara Regional Medical Center Dinasty", Clinics of the Federal State Budgetary Educational Institution SSMU, Samara Regional Clinical Hospital V.D. Seredavin | OTHER | 30 | All | 18 Years ~ 65 Years | Medical Centre Dinasty, Samara, Russian Federation |
| 1426 | Withdrawn | Evaluation of Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized | Covid19 | Biological: A vaccine composed of a recombinant S1 antigen | Phase 2 | Hospital do Coracao, Farmacore Biotecnologia Ltda | OTHER | 0 | All | 18 Years ~ 90 Years | |
| 1425 | Recruiting | Evaluation of Safety and Immunogenicity of a T-Cell Priming Peptide Vaccine Against Coronavirus | COVID-19 | Biological: LD Vehicle-GNP Biological: LD PepGNP-SARSCoV2 Biological: HD Vehicle-GNP Biological: HD PepGNP-SARSCoV2 |
Phase 1 | Emergex Vaccines Holding Ltd., Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland, University of Lausanne Hospitals | INDUSTRY | 26 | All | 18 Years ~ 45 Years | Center for Primary Care and Public Health (Unisante), Lausanne, Vaud, Switzerland |
| 1424 | Recruiting | Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19 | Covid19 | Drug: COR-101 Drug: Placebo |
Phase 2 | Corat Therapeutics Gmbh | INDUSTRY | 45 | All | 18 Years | University Hospital Tubingen, Tubingen, Germany |